Rockefeller Capital Management L.P. Buys 18,925 Shares of Zoetis Inc. $ZTS

Rockefeller Capital Management L.P. lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 3.6% in the second quarter, HoldingsChannel.com reports. The fund owned 548,312 shares of the company’s stock after buying an additional 18,925 shares during the period. Rockefeller Capital Management L.P.’s holdings in Zoetis were worth $85,509,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Citizens Financial Group Inc. RI boosted its holdings in shares of Zoetis by 0.5% during the 2nd quarter. Citizens Financial Group Inc. RI now owns 18,946 shares of the company’s stock valued at $2,955,000 after acquiring an additional 97 shares in the last quarter. Hedeker Wealth LLC boosted its stake in shares of Zoetis by 105.7% during the second quarter. Hedeker Wealth LLC now owns 15,567 shares of the company’s stock valued at $2,428,000 after purchasing an additional 7,999 shares in the last quarter. Cetera Investment Advisers grew its holdings in shares of Zoetis by 1.3% during the second quarter. Cetera Investment Advisers now owns 116,714 shares of the company’s stock worth $18,201,000 after purchasing an additional 1,466 shares during the last quarter. Creative Planning raised its holdings in Zoetis by 0.6% in the 2nd quarter. Creative Planning now owns 89,416 shares of the company’s stock valued at $13,944,000 after buying an additional 560 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in Zoetis by 6.6% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 109,190 shares of the company’s stock worth $17,028,000 after buying an additional 6,786 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Down 0.3%

Shares of NYSE ZTS opened at $120.78 on Friday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a 1 year low of $117.26 and a 1 year high of $181.85. The stock has a market capitalization of $53.23 billion, a P/E ratio of 20.79, a P/E/G ratio of 2.31 and a beta of 0.90. The company has a 50-day moving average price of $140.92 and a 200-day moving average price of $151.47.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.42 billion. During the same period in the previous year, the company posted $1.58 EPS. The company’s revenue for the quarter was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s payout ratio is currently 33.67%.

Analyst Ratings Changes

Several equities analysts recently issued reports on ZTS shares. Argus restated a “buy” rating and issued a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. BTIG Research dropped their price objective on Zoetis from $200.00 to $160.00 and set a “buy” rating on the stock in a research note on Wednesday. UBS Group decreased their target price on Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research note on Wednesday, November 5th. Piper Sandler boosted their price target on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Finally, Morgan Stanley lowered their price objective on shares of Zoetis from $211.00 to $175.00 and set an “overweight” rating for the company in a research note on Monday, November 10th. Six analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, Zoetis has an average rating of “Moderate Buy” and an average target price of $180.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.